Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2025 Earnings Call Transcript February 26, 2026 Nautilus Biotechnology, Inc. beats earnings expectations. Reported EPS is $-0.11, expectations were $-0.14 ...
A precision-engineered decapeptide reshaping how researchers approach melanogenesis modulation at the enzymatic level.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results